- Health & Pharmaceuticals›
- Pharmaceutical Products & Market›
Total R&D costs including costs of capital for select cancer drugs 2017
Premium statistics
Industry-specific and extensively researched technical data (partially from exclusive partnerships).
A paid subscription is required for full access.
Total R&D costs including costs of capital for select cancer drugs 2017
Total R&D costs including 7 percent annual cost of capital for select cancer drugs on the market as of 2017 (in million U.S. dollars)
by Matej Mikulic,
last edited
Jul 22, 2019
This statistic shows the total cost of research and development (R&D) including a 7 percent per annum cost of capital for select cancer drugs that were on the market as of 2017. Alexion Pharmaceuticals' drug Eculizumab had a total R&D cost, including capital, of around 1.09 billion U.S. dollars as of 2017. Total R&D costs without the 7 percent of annual cost of capital stood at some 818 million dollars.
Total R&D costs including 7 percent annual cost of capital for select cancer drugs on the market as of 2017 (in million U.S. dollars)
| Drug name (company, R&D start date) | Cost in million U.S. dollars |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| Drug name (company, R&D start date) | Cost in million U.S. dollars |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
Exclusive Premium statistic
You need a Premium Account for unlimited access.
Full access to 1.5m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
Premium Account
only $49 / month
*
Exclusive content
Exclusive Premium statistic
You need a Premium Account for unlimited access.
Full access to 1.5m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
Premium Account
only $49 / month
*
© Statista 2019
About this statistic
Show source
Download
Settings
Share
Chart type
Datalabels
Share on Social Media
Download started
Please be patient - this may take a moment
Please be patient - this may take a moment
Description
Source
More information
by Matej Mikulic,
last edited
Jul 22, 2019
This statistic shows the total cost of research and development (R&D) including a 7 percent per annum cost of capital for select cancer drugs that were on the market as of 2017. Alexion Pharmaceuticals' drug Eculizumab had a total R&D cost, including capital, of around 1.09 billion U.S. dollars as of 2017. Total R&D costs without the 7 percent of annual cost of capital stood at some 818 million dollars.
- Show sources information
- As a Premium user you get access to the detailed source references and background information about this statistic.
- Show publisher information
- Release date
- November 2017
- Region
- United States
- Survey time period
- as of November 2017
- Supplementary notes
-
This statistic includes only pharmaceutical companies with a single oncologic drug approved by the Food and Drug Administration (FDA). Values are inflation adjusted for 2017 U.S. dollars.
* Alexion later had two drug approvals in the last quarter of 2015; these drugs are not included in this statistic.
** Compound acquired by the company on this date.
Source
- Show sources information
- As a Premium user you get access to the detailed source references and background information about this statistic.
- Show publisher information
- Release date
- November 2017
More information
- Region
- United States
- Survey time period
- as of November 2017
- Supplementary notes
-
This statistic includes only pharmaceutical companies with a single oncologic drug approved by the Food and Drug Administration (FDA). Values are inflation adjusted for 2017 U.S. dollars.
* Alexion later had two drug approvals in the last quarter of 2015; these drugs are not included in this statistic.
** Compound acquired by the company on this date.
Other statistics on the topic
Physicians, Hospitals & Pharmacies
Number of active physicians in the U.S. 2019 by specialty area
+State of Health
Deaths by cancer in the U.S. 1950-2016
Physicians, Hospitals & Pharmacies
Number of oncology specialty physicians in the U.S. 2016
+Pharmaceutical Products & Market
Global top pharmaceutical companies by oncology market share 2017 and 2024
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account!
Premium Account
Your perfect start with Statista
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$49 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Prices do not include sales tax.
Leading companies trust Statista:
Related Studies: Available to Download in PDF or PPTX Format
All Information
in one Presentation
Oncology
- 111 page/s
- English
- pptx
- Detailed references
Everything On "Oncology" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.
I think of Statista as Google for researchers. Statista provides you with the information you search for right away.Dr. Horst Stipp
EVP, Research & Innovation, Advertising Research Foundation
Statistics on "Oncology"
- Cancer facts
The most important statistics
- Leading causes of death worldwide in 2016 (in millions)Global death rate - leading causes 2016
- Number of cancer deaths worldwide in 2018, by major type of cancerCancer deaths worldwide by major type 2018
- Number of U.S. Americans with a history of cancer living between 2004 and 2019 (in millions)U.S. Americans with a history of cancer living 2004-2019
- Number of new cancer cases in the United States from 1999 to 2015*Number of new cancer cases in U.S. from 1999 to 2015
- Deaths by cancer in the U.S. from 1950 to 2016 (per 100,000 population)*Deaths by cancer in the U.S. 1950-2016
- Oncology market
The most important statistics
- Global oncology spending from 2010 to 2018 (in billion U.S. dollars)*Global oncology costs 2010-2018
- Projected growth and spending in the global oncology market between 2014 and 2023Expenditure and growth worldwide in oncology market 2014-2023
- Global oncology therapeutic spending growth in the period 2014-2018, by regionOncology medicine spending growth 2014-2018, by region
- Projected global oncology spending in 2023, by region (in billion U.S. dollars)Predicted oncology spending in 2023, by region
- Emerging cancer diagnostics market size worldwide in 2015 and 2023, by region (in billion U.S. dollars)Emerging cancer diagnostics market size by world region 2015 and 2023
- Growth of the U.S. oncology therapeutic market from 2013 to 2018, by segment (in billion U.S. dollars)Oncology therapeutic market growth U.S. 2013-2018, by segment
- Companies
The most important statistics
- Top 10 pharmaceutical companies based on global oncology revenue in 2017 and 2024 (in million U.S. dollars)Global oncology revenue by top ten pharmaceutical companies 2017 and 2024
- Top 10 pharmaceutical companies based on global oncology market share in 2017 and 2024Global top pharmaceutical companies by oncology market share 2017 and 2024
- Revenue distribution of Roche's Pharmaceuticals division in 2017 and 2018, by therapeutic areaRevenue share of Roche's Pharmaceuticals division by therapy area 2017-2018
- Revenues of biotech company Celgene's top products from 2013 to 2018 (in million U.S. dollars)Celgene's top product revenues 2013-2018
- Bristol-Myers Squibb's top products based on revenue from 2015 to 2018 (in million U.S. dollars)Bristol-Myers Squibb's top products based on revenue 2015-2018
- Venture investments in oncology companies in the U.S. from 2006 to 2017 (in million U.S. dollars)U.S. venture investments in oncology companies 2006-2017
- Amount raised through initial public offerings (IPOs) from oncology companies in the U.S. from 2006 to 2017 (in million U.S. dollars)*U.S. oncology company IPO money raised 2006-2017
- Cancer drugs
The most important statistics
- Top 5 oncology products worldwide based on revenue in 2017 and 2024 (in million U.S. dollars)*Top 5 worldwide oncology products by revenue 2017 and 2024
- Top 5 oncology products worldwide by market share in 2017 and 2024Top 5 worldwide oncology products by market share 2017 and 2024
- Availability of new cancer drugs launched in 2013-2017 in selected countries as of 2018Availability of new cancer drugs by country as of 2018
- Leading U.S. oncology brands based on revenue in 2016 (in million U.S. dollars)Top U.S. oncology products by revenue in 2016
- Number of oncology drugs by treatment cost and number of patients in the U.S. as of 2017Number of cancer drugs by cost and number of patients U.S. 2017
- Research and development
The most important statistics
- Distribution of FDA breakthrough therapy requests by therapy area in 2018FDA on breakthrough therapy requests by therapy area 2018
- Distribution of FDA breakthrough therapy requests granted by therapy area in 2018FDA on breakthrough therapy requests granted by therapy area 2018
- Distribution of late phase oncology pipeline in 2008 and 2018, by typeDistribution of late phase oncology pipeline 2008 vs. 2018 by type
- Number of cancer drugs in development in the United States in select years between 2005 and 2018Number of cancer drugs in development in the U.S. 2005-2018
- Time between R&D start and approval of selected cancer drugs on the market as of 2017 (in years) Time from R&D start to approval of select cancer drugs 2017
- Total R&D costs including 7 percent annual cost of capital for select cancer drugs on the market as of 2017 (in million U.S. dollars)Total R&D costs including costs of capital for select cancer drugs 2017
- Immuno-oncology
The most important statistics
- Top 10 mechanisms of action in R&D pipeline drugs worldwide by number of active compounds in 2019*Worldwide top drug producing mechanisms of action by number of active compounds 2019
- Distribution of the immuno-oncology pipeline worldwide as of 2018, by mechanism of actionDistribution of the immuno-oncology pipeline worldwide 2018, by mechanism of action
- Global cancer immunotherapy market in 2016 and projection for 2022 (in billion U.S. dollars)Global cancer immunotherapy market size 2016 and 2022 forecast
- Market share forecast for top immuno-oncology companies worldwide in 2021*Global cancer immunotherapy sales share by type 2021 forecast
- Top 10 immuno-oncology collaborations worldwide based on value as of 2018 (in billion U.S. dollars)Leading cancer immunotherapy collaborations worldwide by value 2018
- Treatment types
The most important statistics
- Distribution of treatment types for female breast cancer in the U.S. in 2016, by stageDistribution of treatment types for female breast cancer by stage 2016
- Distribution of treatment types for prostate cancer in the U.S. in 2010-2012Distribution of treatment types for prostate cancer 2010-2012
- Distribution of treatment types for colon cancer in the U.S. in 2016, by stageDistribution of treatment types for colon cancer by stage 2016
- Distribution of treatment types for lung cancer in the U.S. in 2016*Distribution of treatment types for lung cancer in the U.S. 2016
- Distribution of treatment types for non-Hodgkin lymphoma in the U.S. in 2013Distribution of treatment types for non-Hodgkin lymphoma 2013
- Physicians and patients
The most important statistics
- Number of oncologists per one million people in select countries as of 2018Number of oncologists per one million people by select country 2018
- Number of active physicians in the U.S. in 2019, by specialty areaNumber of active physicians in the U.S. 2019 by specialty area
- Number of U.S. physicians in oncology specialties in 2016Number of oncology specialty physicians in the U.S. 2016
- Hours per week that oncologists in the U.S. spend seeing patients as of 2018Number of hours U.S. oncologists spend a week seeing patients 2018
- Minutes that oncologists in the U.S. spend with each patient as of 2018Number of minutes U.S. oncologists spend with each patient 2018
- Medication usage among patients with cancer in selected countries as of 2018*Cancer patients using medication in select countries 2018
- Lifestyle among patients with cancer in selected countries as of 2018*Cancer sufferers based on lifestyle habits by select country 2018
- Average length of stay in U.S. hospitals per inpatient cancer cases from 2008 to 2017 (in days)Inpatient average length of stay in U.S. hospitals by cancer type 2008-2017
Discover Statista
Need help with using Statista for your research?
Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statistics
- Revenue as a part of R&D spending for select cancer drugs 2017
- Revenue since approval for select cancer drugs 2017
- Unsuccessful developing melanoma drugs in the U.S. 1998-2014
- Unsuccessful developing lung cancer drugs in the U.S. 1998-2014
- USA: Active ingredients in anti-cancer drugs 2004-2013
- Average prices of Gleevec - selected countries 2013
- Number of new cancer pharmaceuticals approved by EMA in Sweden 2014-2017
- Proportion of cancer drugs on the world pharmaceutical market
- Unsuccessful developing brain cancer drugs in the U.S. 1998-2014
- Age distribution of oncology clinical trials globally 2008-2013, by cancer
- Italy: consumption of cancer drugs 2017, by region
- Gender distribution of oncology clinical trials globally 2008-2013, by cancer
- Geographic distribution of oncology clinical trials 2008-2013, by cancer
- Anti-cancer drugs estimated market size in South Korea 2014-2020
- Italy: number of clinical trials for rare diseases 2017, by type of drug
- Cancer drugs on the world market 2010
- Worldwide revenue of cancer drugs
- Herbal raw material export value in South Korea 2012-2017
- Testosterone use in Canada per 1,000 population 2000-2011
- Monthly value of gland exports from Finland 2018
Studies
- Oncology
- Personalized medicine
- Animal testing in the United Kingdom
- Pharmaceutical trends in Europe
- Complementary Medicines Australia 2017/18 Federal pre-Budget Submission
- Complementary Medicines Australia 2016/17 Federal pre-Budget Submission
- Complementary Medicines Australia 2015/16 Federal pre-Budget Submission
Statistics on "Oncology"
- Leading causes of death worldwide in 2016 (in millions)
- Number of cancer deaths worldwide in 2018, by major type of cancer
- Number of U.S. Americans with a history of cancer living between 2004 and 2019 (in millions)
- Number of new cancer cases in the United States from 1999 to 2015*
- Deaths by cancer in the U.S. from 1950 to 2016 (per 100,000 population)*
- Global oncology spending from 2010 to 2018 (in billion U.S. dollars)*
- Projected growth and spending in the global oncology market between 2014 and 2023
- Global oncology therapeutic spending growth in the period 2014-2018, by region
- Projected global oncology spending in 2023, by region (in billion U.S. dollars)
- Emerging cancer diagnostics market size worldwide in 2015 and 2023, by region (in billion U.S. dollars)
- Growth of the U.S. oncology therapeutic market from 2013 to 2018, by segment (in billion U.S. dollars)
- Top 10 pharmaceutical companies based on global oncology revenue in 2017 and 2024 (in million U.S. dollars)
- Top 10 pharmaceutical companies based on global oncology market share in 2017 and 2024
- Revenue distribution of Roche's Pharmaceuticals division in 2017 and 2018, by therapeutic area
- Revenues of biotech company Celgene's top products from 2013 to 2018 (in million U.S. dollars)
- Bristol-Myers Squibb's top products based on revenue from 2015 to 2018 (in million U.S. dollars)
- Venture investments in oncology companies in the U.S. from 2006 to 2017 (in million U.S. dollars)
- Amount raised through initial public offerings (IPOs) from oncology companies in the U.S. from 2006 to 2017 (in million U.S. dollars)*
- Top 5 oncology products worldwide based on revenue in 2017 and 2024 (in million U.S. dollars)*
- Top 5 oncology products worldwide by market share in 2017 and 2024
- Availability of new cancer drugs launched in 2013-2017 in selected countries as of 2018
- Leading U.S. oncology brands based on revenue in 2016 (in million U.S. dollars)
- Number of oncology drugs by treatment cost and number of patients in the U.S. as of 2017
- Distribution of FDA breakthrough therapy requests by therapy area in 2018
- Distribution of FDA breakthrough therapy requests granted by therapy area in 2018
- Distribution of late phase oncology pipeline in 2008 and 2018, by type
- Number of cancer drugs in development in the United States in select years between 2005 and 2018
- Time between R&D start and approval of selected cancer drugs on the market as of 2017 (in years)
- Total R&D costs including 7 percent annual cost of capital for select cancer drugs on the market as of 2017 (in million U.S. dollars)
- Top 10 mechanisms of action in R&D pipeline drugs worldwide by number of active compounds in 2019*
- Distribution of the immuno-oncology pipeline worldwide as of 2018, by mechanism of action
- Global cancer immunotherapy market in 2016 and projection for 2022 (in billion U.S. dollars)
- Market share forecast for top immuno-oncology companies worldwide in 2021*
- Top 10 immuno-oncology collaborations worldwide based on value as of 2018 (in billion U.S. dollars)
- Distribution of treatment types for female breast cancer in the U.S. in 2016, by stage
- Distribution of treatment types for prostate cancer in the U.S. in 2010-2012
- Distribution of treatment types for colon cancer in the U.S. in 2016, by stage
- Distribution of treatment types for lung cancer in the U.S. in 2016*
- Distribution of treatment types for non-Hodgkin lymphoma in the U.S. in 2013
- Number of oncologists per one million people in select countries as of 2018
- Number of active physicians in the U.S. in 2019, by specialty area
- Number of U.S. physicians in oncology specialties in 2016
- Hours per week that oncologists in the U.S. spend seeing patients as of 2018
- Minutes that oncologists in the U.S. spend with each patient as of 2018
- Medication usage among patients with cancer in selected countries as of 2018*
- Lifestyle among patients with cancer in selected countries as of 2018*
- Average length of stay in U.S. hospitals per inpatient cancer cases from 2008 to 2017 (in days)
- Percentage of patients whose tumors are driven by certain genetic mutations as of 2016, by cancer type
- Revenue as a percentage of R&D spending for select cancer drugs on the market as of 2017
- Total revenue since approval for select cancer drugs on the market as of 2017 (in million U.S. dollars)
- Number of unsuccessful melanoma drugs in development in the United States from 1998 to 2014
- Number of unsuccessful lung cancer drugs in the United States from 1998 to 2014
- Number of approvals for new active ingredients in cancer drugs in the U.S. from 2004 to 2013
- Average prices of Gleevec in selected countries in 2013 (in U.S. dollars)
- Number of new cancer pharmaceuticals approved by EMA (European Medicines Agency) in Sweden from 2014 to 2017
- Proportion of cancer drugs on the world pharmaceutical market in 2003 and 2009 (in percent)
- Number of unsuccessful brain cancer drugs in development in the United States from 1998 to 2014
- Age distribution of clinical trials for select types of oncology drugs approved between 2008 and 2013, by cancer
- Level of consumption of cancer drugs in Italy in 2017, by region (in DDD* per 1,000 inhabitants per day)
- Gender distribution of clinical trials for select types of oncology drugs approved worldwide between 2008 and 2013, by cancer
- Regional distribution of clinical trials for select types of oncology drugs approved between 2008 and 2013, by cancer
- Estimated size of the anti-cancer drugs market in South Korea from 2014 to 2020 (in trillion South Korean won)
- Number of clinical trials* to treat rare diseases in Italy in 2017, by type of drug
- Proportion of cancer drugs on the world market from 2004 to 2010
- Revenue of cancer drugs worldwide in 2003 and 2009 (in billion U.S. dollars)
- Value of herbal medicine raw materials exported from South Korea between 2012 and 2017 (in million U.S. dollars)
- Testosterone use in Canada from 2000 to 2011 (in monthly doses of per 1,000 population)*
- Monthly value of glands and other organs for organotherapeutic use exported from Finland from December 2017 to December 2018 (in 1,000 U.S. dollars)
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Related topics
About Statista
Statista offers dossiers and reports on over 170 industries. With Statista you are always able to make informed decisions and boost your work efficiency.
Internet & Telecommunications
- Social Media
- E-Commerce
- Online Video & Entertainment
- Advertising & Marketing
Consumer Goods & FMCG
- Alcoholic Beverages
- Cleaning Products
- Cosmetics & Personal Care
- Food & Nutrition
Retail & Trade
- Health & Hygiene
- International Trade
- Shopping Behavior
- Sports & Leisure
Travel, Tourism & Hospitality
- Business Travel
- Leisure Travel
- Accomodation
- Restaurants
Society
- Demographics
- Economy
- Education & Science
- Politics & Government
Transportation & Logistics
- Aviation
- Rail Transport
- Vehicles & Road Traffic
- Water Transport
Save statistic in .XLS format
You can only download this statistic as a Premium user.
Save statistic in .PNG format
You can only download this statistic as a Premium user.
Save statistic in .PDF format
You can only download this statistic as a Premium user.
Show source references
As a Premium user you get access to the detailed source references and background information about this statistic.
Show details about this statistic
As a Premium user you get access to background information and details about the release of this statistic.
Bookmark statistics
As soon as this statistic is updated, you will immediately be notified via e-mail.
Change statistics options
You need at least a Premium Account to use this feature.
Exclusive Corporate feature
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Corporate Account
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.